KYMR (Kymera Therapeutics) Stock Based Compensation: $61.68 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYMR Kymera Therapeutics Inc KYMR
46 GF Score
Price $103.26
GF Value $24.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kymera Therapeutics Stock Based Compensation?

Kymera Therapeutics KYMR -3.18% 46 Stock Based Compensation is $61.68 Mil as of Mar. 2026. GuruFocus rates KYMR with a GF Score™ of 46/100 and a GF Value™ of $24.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Kymera Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $16.01 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $61.68 Mil.

Kymera Therapeutics Stock Based Compensation Related Terms

Kymera Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Kymera Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kymera Therapeutics Stock Based Compensation Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 24.97 35.48 43.12 55.01 59.90

Kymera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.23 15.42 15.80 14.45 16.01
KYMR
46GF Score
Kymera Therapeutics Inc KYMR
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kymera Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.68 Mil.

What does a Stock Based Compensation of $61.68 Mil mean?
Kymera Therapeutics (KYMR) has a Stock Based Compensation of $61.68 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Kymera Therapeutics and its competitors.
Is Kymera Therapeutics' Stock Based Compensation too high?
Kymera Therapeutics' current Stock Based Compensation is $61.68 Mil. Overall, Kymera Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kymera Therapeutics' Stock Based Compensation compare to PRAX and SYRE?
Kymera Therapeutics' Stock Based Compensation of $61.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Kymera Therapeutics and its competitors. Kymera Therapeutics's current Stock Based Compensation is $61.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kymera Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Kymera Therapeutics (KYMR) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.38, compared to a current price of $103.26 — trading 323.5% above its estimated fair value. The current Stock Based Compensation is $61.68 Mil. Kymera Therapeutics' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Kymera Therapeutics (KYMR), the current Stock Based Compensation is $61.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kymera Therapeutics (KYMR) Overvalued in 2026?

Based on GuruFocus' analysis, Kymera Therapeutics stock appears to be overvalued. The current stock price of $103.26 is trading 323.5% above its estimated GF Value™ of $24.38. GuruFocus considers Kymera Therapeutics to be Significantly Overvalued.

Key valuation signals for KYMR:

  • Stock Based Compensation: $61.68 Mil
  • GF Value™: $24.38 vs. price of $103.26 (323.5% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the KYMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kymera Therapeutics Business Description

Address 500 North Beacon Street, 4th Floor, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
46GF Score

Get the complete analysis for KYMR

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$103.26
Price
$24.38
GF Value